The Centers for Medicare and Medicaid Services will work to ensure that new generics and biosimilars that could disrupt or delay price negotiation for brands are not encumbered by distribution or sales limits dictated by the reference product manufacturer, the agency says in its initial guidance for the program.
Game On: Medicare Will Parry Manufacturer Efforts To Sidestep Price Negotiation, Guidance Says
CMS will need to continue to be ‘savvy’ to strategies brand manufacturers already employ to shape the landscape for generic and biosimilar competition, policy expert says.
